Description
Usage:
What is Super Vilitra 80mg?
Super Vilitra is a mix of (Vardenafil and Dapoxetine). Super Vilitra is a dynamic pharmaceutical blend, harnessing the power of Vardenafil and Dapoxetine to tackle both erectile dysfunction and premature ejaculation.
With Vardenafil enhancing blood flow for a robust erection and Dapoxetine ensuring control over climax timing, this medication provides a dual-action solution. Known for its extended efficacy, It offers users an enhanced sexual experience with a single dose.
It is primarily used to address two common sexual health concerns:
-Erectile Dysfunction (ED): The Vardenafil component in the medicine acts as a phosphodiesterase type 5 (PDE5) inhibitor. It facilitates the relaxation of the blood vessels in the penile region, promoting increased blood flow.
This mechanism helps individuals with ED achieve and sustain a firm erection, enhancing overall sexual performance.
-Premature Ejaculation (PE): The inclusion of Dapoxetine, a selective serotonin reuptake inhibitor (SSRI), in Super Vilitra aims to delay ejaculation. Increasing serotonin levels in the brain, provides users with better control over the timing of climax, addressing issues related to premature ejaculation.
Dosage:
Swallow the tablet whole with a glass of water. Do not chew, crush, or break the tablet. You may take this ED tablet with or without food. Take it at least one hour before you plan to have sex. kindly avoid taking over dose to get more effects, it will be dangerous to you health. do not take more than recommended dose and duration.
Side Effects:
Super Vilitra 80mg , like any medication, may be associated with potential side effects. It’s important to be aware of these side effects and seek medical attention if they persist or worsen. Common side effects may include Headache, Dizziness, Flushing (Redness of the Face), Nasal Congestion, Nausea, Digestive Issues, Vision Change,Priapism: In rare cases, an erection lasting longer than 4 hours (priapism) can occur.
Reviews
There are no reviews yet.